The NMRAL1 Knockout Raji Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout population derived from the human Raji B lymphoblastoid line through targeted disruption of the NMRAL1 gene. This polyclonal format offers a diverse knockout model, avoiding the biases of monoclonal expansion while retaining a stable loss-of-function background. It is well-suited for systematic analyses of NMRAL1-dependent processes, including metabolic flux, signal transduction, and drug response assays, without the need for single-cell cloning.
The Raji parental line originates from an EBV-positive Burkitt lymphoma and serves as a principal model for B-cell immunology and lymphomagenesis. These suspension-adapted lymphoblastoid cells maintain hallmark characteristics of malignant B lymphocytes, such as active signaling through survival and proliferation pathways, making them an ideal context for investigating tumor suppressor genes and metabolic vulnerabilities in lymphoma biology.
NMRAL1 encodes a redox-sensitive scaffold protein that negatively regulates arginine metabolism by binding and inhibiting argininosuccinate synthase 1 (ASS1). Under basal conditions, this interaction constrains arginine availability and nitric oxide (NO) synthesis via NOS2. Following DNA damage or p53 activation, NMRAL1 releases ASS1, leading to increased arginine flux and NO production, which in turn potentiates p53-mediated cell cycle arrest and apoptosis. The 14-3-3 protein family interacts with NMRAL1 and modulates its subcellular distribution, adding a layer of post-translational control. This positions NMRAL1 as a stress-responsive tumor suppressor linking metabolic checkpoints to the DNA damage machinery.
In the Raji background, NMRAL1 knockout enables dissection of how arginine-NO signaling intersects with B-cell survival, transformation, and therapeutic response. Since Burkitt lymphoma cells may rely on intact DNA damage checkpoints, NMRAL1 loss could reveal mechanisms of chemoresistance or altered sensitivity to arginine deprivation therapies. Additionally, this model facilitates exploration of interactions between EBV latency programs and the host metabolic stress pathways governed by NMRAL1.
These polyclonal knockout cells support a range of functional assays: Western blot and RT-qPCR for confirming gene disruption; co-immunoprecipitation to assess ASS1 binding; arginine uptake and Griess assays for metabolic and NO profiling; flow cytometry (Annexin V) and MTS/XTT for apoptosis and proliferation analyses under genotoxic stress. Xenograft models allow in vivo evaluation of tumor growth and arginine dependency. The product is valuable for drug target validation in arginine-auxotrophic malignancies, including hepatocellular carcinoma and lymphomas, and for broader immune metabolism research. For technical support, contact Ascent Research.
